Clinically relevant drug-drug interactions and the risk for drug adverse effects among home-dwelling older persons with and without type 2 diabetes by Ikäheimo, Ilona et al.
J Clin Pharm Ther. 2019;44:735–741.	 wileyonlinelibrary.com/journal/jcpt	 	 | 	735© 2019 John Wiley & Sons Ltd
 
Received:	29	March	2019  |  Accepted:	30	April	2019
DOI: 10.1111/jcpt.12854  
O R I G I N A L  A R T I C L E
Clinically relevant drug‐drug interactions and the risk for drug 
adverse effects among home‐dwelling older persons with and 
without type 2 diabetes
Ilona Ikäheimo MSc (Pharm)1 |   Merja Karjalainen MD2,3 |   Miia Tiihonen PhD (Pharm)1  |  
Maija Haanpää MD, PhD4,5 |   Hannu Kautiainen MSc6,8 |   Juha Saltevo MD, PhD7 |   
Pekka Mäntyselkä MD, PhD2,8
1School of Pharmacy, University of Eastern 
Finland, Kuopio, Finland
2Institute of Public Health and Clinical 
Nutrition, General Practice, University of 
Eastern Finland, Kuopio, Finland
3Inner Savo Health Center, Suonenjoki, 
Finland
4Ilmarinen Mutual Pension Insurance 
Company, Vantaa, Finland
5Department of Neurosurgery, Helsinki 
University Hospital, Helsinki, Finland
6Unit of Primary Health Care, Helsinki 
University Central Hospital, Helsinki, Finland
7Central Finland Central Hospital, Jyväskylä, 
Finland
8Primary Health Care Unit, Kuopio 
University Hospital, Kuopio, Finland
Correspondence
Miia Tiihonen, School of Pharmacy, 
University of Eastern Finland, Kuopio, 
Finland.
Email: miia.tiihonen@uef.fi
Funding information
M.K has received a personal grant from the 
North Savo Cultural Foundation.
Abstract
What is known and objective: Polypharmacy and age are known to increase the risk 
for potential drug interactions. Type 2 diabetes has been associated with polyphar‐
macy and several comorbidities. Currently, there is no information on whether the 
frequency of clinically relevant drug‐drug interactions and the risk for drug adverse 
effects differ between older persons with and without diabetes. The aim of this 
study was to investigate the frequency of drug‐drug interactions and the risk for 
drug adverse effects in these two groups in primary care.
Methods: The basic study population consisted of Finnish home‐dwelling primary 
care	patients	aged	≥	65	years	(N	=	3039).	For	each	person	with	diabetes,	two	controls	
were selected with adjusted age and gender. To collect data, electronic primary care 
patient records, a structured health questionnaire and a structured health examina‐
tion	conducted	by	a	physician	were	utilized.	Using	the	SFINX-PHARAO® database, 
drug‐drug interactions and the risk for drug adverse effects were evaluated in 182 
persons with type 2 diabetes and 176 persons without diabetes.
Results and discussion: There were no significant differences in the frequency of 
drug‐drug interactions or the risk for drug adverse effects in persons with and with‐
out	 diabetes.	 At	 least	 one	 clinically	 relevant	 interaction	was	 found	 in	 81	 (44.5%)	
persons	with	diabetes	and	73	(41.5%)	persons	without	diabetes.	The	most	common	
drugs	causing	interactions	included	non-steroidal	anti-inflammatory	drugs	(NSAIDs)	
and warfarin.
What is new and conclusion: There is no difference in the frequency of drug‐drug 
interactions or risk for drug adverse effects in older home‐dwelling persons with and 
without diabetes. Due to common comorbidities and commonly used drugs among 
persons	with	diabetes,	drug-drug	interactions	involving	warfarin	or	NSAIDs	in	par‐
ticular should be carefully monitored to avoid drug adverse effects.
K E Y W O R D S
adverse effect, diabetes, drug–drug interactions, elderly
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1  | WHAT IS KNOWN AND OBJEC TIVE
The number of the world’s population aged over 60 years will reach 
2 billion in 2050.1 It is estimated that in 2014 there were 422 million 
adults with diabetes and the number is still increasing.2 The ageing 
of the population will certainly increase the prevalence of diabetes in 
older adults.3 Older persons with diabetes are known to have several 
comorbidities, for example coronary heart disease and stroke, more 
frequently than those without diabetes.4
Older age is associated with polypharmacy and multimorbidity 
as well as the risk for drug adverse effects.5‐7 Polypharmacy and 
age increase the risk for potential drug interactions.8 Moreover, re‐
search has found an association between polypharmacy and type 2 
diabetes, although polypharmacy is often justified due to the current 
guidelines for diabetes treatment.9 Diabetes has been shown to in‐
crease the risk for admission to a medical emergency department 
due to drug adverse effects in older persons.10
There are only a few previous studies concerning drug‐drug 
interactions among older persons with diabetes.11,12	 As	 far	 as	we	
know, no study comparing drug‐drug interactions and the risk for 
drug adverse effects between older persons with and without dia‐
betes has been conducted. Therefore, the aim of this study was to 
investigate the frequency of drug‐drug interactions and the risk for 
drug adverse effects among home‐dwelling older persons with and 
without type 2 diabetes in primary care.
2  | METHODS
2.1 | Study population
This	study	is	a	part	of	the	Inner	Savo	DM65+	(ISDM)	study.	The	basic	
population of the ISDM study consisted of older home‐dwelling per‐
sons	 (N	=	3039)	 living	 in	 Inner	Savo	 in	Finland.	The	study	popula‐
tion was gathered from primary care electronic patient records by 
identifying	persons	with	diabetes	(N	=	540)	according	to	diagnostic	
codes E10 and E11 of the International Classification of Diagnoses 
(ICD-10).13 For each person with diabetes, two controls with ad‐
justed age and gender were selected. Persons suffering from the 
terminal stages of cancer or other terminal illnesses were excluded, 
in addition to persons hospitalized or living permanently in institu‐
tional	care.	A	structured	health	questionnaire	was	posted	to	1,417	
persons,	527	with	diabetes	and	890	without	diabetes	in	August	and	
September	of	2015	(response	rate	76.5%).	After	the	questionnaire,	
259 persons with diabetes and 259 persons without diabetes were 
invited	to	a	health	examination	conducted	by	a	physician.	A	complete	
set of data were available from 187 persons with diabetes and 176 
persons	without	diabetes.	To	study	drug-drug	interactions	(DDI)	and	
the risk of drug adverse effects among persons with type 2 diabe‐
tes,	persons	with	type	1	diabetes	(N	=	5)	were	excluded.	Ultimately,	
drug‐drug interactions and the risk for drug adverse effects were 
examined among 358 persons, of whom 182 had type 2 diabetes and 
176 did not have diabetes.
2.2 | Measurements and tools
The risk for clinically significant drug‐drug interactions and drug ad‐
verse	effects	were	evaluated	by	using	the	SFINX-PHARAO® data‐
base	(Medbase	Ltd).	The	Swedish	Finnish	Interaction	X-referencing	
(Sfinx®,	 currently	 INXBASE)	 database	was	developed	 in	 co-opera‐
tion between Finnish and Swedish experts.14 DDIs in the database 
are	classified	based	on	their	severity	(A-D)	and	the	level	of	documen‐
tation	(0-4).	Class	A	interactions	are	minor	interactions	or	clinically	
irrelevant interactions. The clinical outcome of class B interactions 
may vary and/or be uncertain. Class C interactions are clinically rel‐
evant but can be handled, for example by dose adjustments. Class D 
interactions include interactions that are best avoided. In this study, 
class C and class D interactions are regarded to be clinically relevant 
drug‐drug interactions. The level of documentation is highest with 
number 4, when the interaction has been documented in controlled 
studies in relevant patient populations, and lowest with number 0, 
when the interaction has been documented from extrapolation from 
studies with similar drugs. The frequency of interactions in the study 
population and the total number of interactions were calculated.
The	Pharmacological	Risk	Assessment	Online	System	(Pharao®, 
currently	 RiskBase)	 database	 was	 used	 to	 investigate	 the	 risk	 for	
drug adverse effects. The database is developed by the Sfinx® work‐
ing group.15 There are nine different common and/or severe adverse 
effects in the database including bleeding, constipation, anticholin‐
ergic side effects, orthostatic hypotension, sedation, QT prolonga‐
tion, seizures, serotonergic side effects and nephrotoxicity. The risk 
of	an	adverse	effect	 is	 classified	 from	A	 to	D,	class	A	meaning	no	
increased risk and class D meaning high risk for an adverse effect. 
In addition, each drug in the database has been scaled from 0 to 3 
based on the strength of the pharmacological effect to increase the 
risk. In this study, the frequency of having class D, that is high risk, for 
each adverse effect based on a person’s medication was calculated.
Background	variables	(sex,	age	and	education	years),	amount	of	
exercise, ability to move without assistive aid, smoking, consump‐
tion of alcohol, depressive symptoms and health‐related quality of 
life were determined using a structured health questionnaire. The 
Kasari’s FIT index was used to evaluate the duration, efficiency and 
frequency of exercise.16	Alcohol	consumption	and	depressive	symp‐
toms	were	assessed	using	the	Alcohol	Use	Disorders	Identification	
Test	(AUDIT-C)	and	Geriatric	Depression	Scale	(GDS-15).17,18 Quality 
of life was evaluated using the EuroQol EQ‐5D questionnaire.19 
Cognitive functioning was assessed based on the Mini‐Mental State 
Examination	(MMSE).20	The	Lawton	Instrumental	Activities	of	Daily	
Living	Scale	(IADL)	was	used	to	evaluate	a	person’s	ability	to	func‐
tion.21	MMSE	and	IADL	tests	were	part	of	the	health	examination.
The physical health examinations were standardized and con‐
ducted by MK. Blood pressure was determined from an orthostatic 
hypotension test. The test was made after 10 minutes of rest in a 
lying position, 1 minute at a time in a sitting position and 3 minutes at 
a time in a standing position. The measurement result of the sitting 
position	(1	minute	at	a	time)	was	used	as	a	person’s	blood	pressure.	
Body	mass	index	(BMI)	was	determined	from	weight	and	height	(kg/
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m2).	Comorbidities	were	verified	by	MK	from	the	electronic	patient	
records, and ten different comorbidities were confirmed: heart 
diseases, cerebrovascular accident, peripheral arterial diseases, 
musculoskeletal diseases, pulmonary diseases, cancer, neurological 
diseases, gastrointestinal diseases, dementia and psychiatric dis‐
eases.	A	pharmacist	reviewed	the	medication	of	each	participant.
Laboratory	tests	were	performed	by	Eastern	Finland	Laboratory	
Centre	 (ISLAB),	 which	 is	 licensed	 by	 the	 Finnish	 Accreditation	
Service.	Total	LDL	and	HDL	cholesterol	levels	along	with	triglycerides	
(fP-Kol,	fP-Kol-LDL,	fP-Kol-HDL	and	fP-Trigly)	were	measured.	The	
values are based on fasting samples.
2.3 | Ethical considerations
The ethical permission for the ISDM study protocol was granted by 
the Research Ethics Committee of Northern Savo Hospital District, 
Kuopio, Finland. The study was conducted in accordance with the 
Declaration of Helsinki. Each participant signed an informed consent 
form, and returning the health questionnaire was voluntary. Data 
were handled and analysed anonymously.
2.4 | Statistical analysis
ibm spss	 Statistics	 (25)	 for	Windows	 was	 used	 for	 processing	 and	
analysing the data. The analysis included descriptive statistics, that 
is frequencies and cross‐tabulations. Differences in frequencies be‐
tween groups were tested using a chi‐squared test. P‐values of 0.05 
or less were considered statistically significant.
3  | RESULTS AND DISCUSSION
Complete	 data	 were	 available	 from	 358	 patients,	 182	 (50.8%)	 of	
whom	had	type	2	diabetes	and	176	 (49.2%)	who	did	not	have	dia‐
betes. The characteristics of the study population are presented in 
Table	1.	91	(50%)	of	the	persons	with	diabetes	and	116	(66%)	of	the	
persons without diabetes were men. Persons with diabetes had a 
higher BMI, lower level of physical activity, were less frequently able 
to move without assistive aid and smoked less. Persons with dia‐
betes	had	 lower	 total	 LDL	and	HDL	cholesterol	 levels,	while	 their	
triglyceride levels were higher. Heart diseases were more common 
among persons with diabetes. Persons with diabetes had a lower 
mean	AUDIT-C	score,	meaning	less	consumption	of	alcohol,	a	higher	
mean GDS‐15 score, meaning more depressive symptoms and a 
lower mean EQ‐5D score, indicating lower health‐related quality of 
life. Persons with diabetes used more drugs on a regular basis and 
used more drugs as needed. Relative portions of drugs used in dif‐
ferent	 ATC	 classes	 among	 persons	with	 and	without	 diabetes	 are	
shown in Figure 1. The number of persons with diabetes using the 
most commonly used drugs among persons with diabetes together 
with corresponding numbers of persons without diabetes using 
these drugs is shown in Table 2. The frequency of use differed to a 
great extent between persons with and without diabetes, especially 
for drugs used in cardiovascular diseases.
Seventy-five	persons	with	diabetes	(41.2%)	and	69	persons	with‐
out	diabetes	(39.2%)	had	at	least	one	interaction	classified	as	a	class	
C interaction, meaning an interaction requiring, for example dose 
adjustments	(P	=	0.699).	13	(7.1%)	persons	with	diabetes	and	9	(5.1%)	
persons without diabetes had at least one interaction classified as 
a class D interaction, meaning an interaction to be best avoided 
(P	=	0.424).	When	combined,	81	(44.5%)	persons	with	diabetes	and	
73	(41.5%)	persons	without	diabetes	had	at	least	one	drug-drug	in‐
teraction considered to be clinically relevant, that is a class C or class 
D	interaction	(P	=	0.563).	One	person	could	have	had	more	than	one	
interaction,	ranging	from	1	to	7	interaction(s)	per	person	with	diabe‐
tes	and	from	1	to	9	interaction(s)	per	person	without	diabetes.
The number of times different drugs were involved in the clinically 
relevant drug‐drug interactions is shown in Table 3. The most common 
drugs causing interactions are listed in the Table. The total number of 
clinically	relevant	interactions	(class	C	or	D	interaction	in	Sfinx® data‐
base)	was	183	in	persons	with	diabetes	and	150	in	persons	without	
diabetes. Of 183 interactions in persons with diabetes, 170 were class 
C and 13 were class D interactions. Of 150 interactions in persons 
without diabetes, 140 were class C and 10 were class D interactions. 
Most common were interactions with non‐steroidal anti‐inflammatory 
drugs	(NSAIDs)	along	with	interactions	with	warfarin.	The	most	com‐
mon interactions with warfarin were interactions with paracetamol 
and	simvastatin.	NSAID	interactions	consisted	mostly	of	interactions	
with acetylsalicylic acid and drugs used in cardiovascular diseases 
(eg,	ACE	 inhibitors,	 angiotensin	 II	 receptor	blockers	and	β-blockers).	
Interactions with warfarin along with interactions with selective sero‐
tonin	uptake	inhibitors	(SSRI)	or	serotonin	and	noradrenaline	uptake	
inhibitors	(SNRIs)	were	more	common	among	persons	with	diabetes.
The frequency of high risk for drug adverse effects is shown 
in Table 4. Persons with diabetes had a high risk for constipation 
(P	=	0,039)	more	frequently.	The	risk	for	bleeding,	anticholinergic	side	
effects, orthostatic hypotension, sedation, QT prolongation, seizures 
and serotonergic side effects were also more frequent among persons 
with diabetes, but these differences were statistically insignificant.
Our main findings are that there were no significant differences 
in the frequency of drug‐drug interactions or high risk for drug ad‐
verse effects among persons with and without diabetes. However, 
drug use was more common among persons with diabetes compared 
to persons without diabetes and there were some differences in 
drugs with significantly increased risk for interactions.
Our study shows that potential drug‐drug interactions are less 
frequent among home‐dwelling persons with diabetes when com‐
pared to older persons with diabetes in home health care studied 
by Ibrahim et al,12 where potentially moderate drug‐drug interac‐
tions	 were	 recorded	 in	 92.8%	 of	 patients	 and	 potentially	 severe	
drug-drug	 interactions	were	found	 in	38.8%	of	patients.	However,	
it should be noted that the interaction database used was different, 
and therefore, the classification of interactions may not be equiv‐
alent.	 Clinically	 relevant	 interactions	 using	 the	 SFINX-PHARAO® 
database	were	 found	 in	74%	of	 the	home	care	patients	 in	a	study	
conducted	in	Finland	by	Auvinen	et	al,22 though the patients used 
more drugs and were older and more fragile than in our study. In 
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the present study, the frequency of interactions to be best avoided 
(class	D	interactions)	was	slightly	higher	among	persons	with	diabe‐
tes	(7.1%)	whereas	the	frequency	among	persons	without	diabetes	
(5.1%)	was	similar	to	the	study	conducted	by	Hosia-Randell	et	al,23 
which	studied	DDIs	among	nursing	home	residents	(4.8%).	The	fre‐
quency	of	serious	interactions	(7.1%)	among	persons	with	diabetes	
was consistent with previous drug‐drug interaction studies among 
persons	with	diabetes	 (5.1%-17.5%).	However,	a	direct	comparison	
is not possible since the classification and frequency of interactions 
were determined using different methods and the study populations 
differed from our study population.11,24
As	for	drug-drug	 interactions	 in	different	drug	classes,	 interac‐
tions with warfarin were more common among persons with dia‐
betes, which is probably related to the higher prevalence of heart 
diseases and use of antithrombotic agents among persons with dia‐
betes.	In	our	study	population,	25.3%	of	persons	with	diabetes	and	
21.0%	of	persons	without	diabetes	had	a	high	 risk	 for	bleeding.	A	
slightly higher frequency of risk for bleeding among persons with 
diabetes may be a consequence of higher frequency of warfarin 
interactions. Concurrent use of warfarin and warfarin‐potentiating 
medication, for example antiplatelet or analgesic, has been associ‐
ated with more haemorrhagic events and therefore higher treatment 
TA B L E  1   Descriptive characteristics of the study population
 
Diabetes mellitus
P‐Value*Diabetes N = 182 No diabetes N = 176
Men,	n	(%) 91	(50) 116	(66) 0.002
Age,	mean	(SD) 74	(7) 74	(6) 0.96
Education	years,	mean	(SD) 9.5	(3.2) 9.8	(3.3) 0.38
Body mass index, kg/m2,	mean	(SD) 31.2	(5.9) 27.6	(5.0) <0.001
Physical	activity,	Kasari	FIT	index,	mean	(SD) 31	(20) 43	(22) <0.001
Able	to	move	without	assistive	aid,	n	(%) 124	(75) 147	(88) 0.002
Smoking	n	(%) 11	(6) 24	(14) 0.016
Blood	pressure,	mean	(SD)
Systolic 152	(22) 156	(22) 0.072
Diastolic 87	(11) 90	(12) 0.059
Total	cholesterol,	mmol/l,	mean	(SD) 4.60	(1.12) 4.91	(1.01) 0.006
LDL,	mean	(SD) 2.71	(0.99) 3.00	(0.84) 0.004
HDL,	mean	(SD) 1.38	(0.42) 1.56	(0.44) <0.001
Triglycerides,	mean	(SD) 1.53	(0.66) 1.14	(0.51) <0.001
Comorbidities	n	(%)
Heart diseases 149	(82) 118	(67) <0.001
Cerebrovascular accident 4	(2) 6	(3) 0.54
Peripheral arterial disease 5	(3) 6	(3) 0.72
Musculoskeletal diseases 70	(38) 64	(36) 0.68
Pulmonary diseases 19	(10) 17	(10) 0.81
Cancer 13	(7) 14	(8) 0.77
Neurological diseases 7	(4) 3	(2) 0.34
Gastrointestinal diseases 2	(1) 1	(1) 0.99
Dementia 8	(4) 2	(1) 0.11
Psychiatric diseases 8	(4) 3	(2) 0.22
AUDIT-C,	mean	(SD) 1.8	(1.9) 2.5	(2.4) 0.007
IADL,	mean	(SD) 10.8	(4.7) 10.9	(4.0) 0.90
MMSE,	mean	(SD) 26.9	(3.3) 27.4	(3.2) 0.18
GDS-15,	mean	(SD) 3.4	(3.1) 2.1	(2.4) <0.001
EQ-5D,	mean	(SD) 0.758	(0.166) 0.829	(0.162) <0.001
Drugs	used	on	a	regular	basis,	mean	(SD) 7.1	(3.1) 4.2	(2.9) <0.001
Drugs	used	as	needed,	mean	(SD) 2.7	(2.5) 2.1	(2.0) 0.021
Abbreviations:	EQ-5D,	EuroQol	Questionnaire;	GDS-15,	Geriatric	Depression	Scale;	IADL,	Lawton	Instrumental	Activities	of	Daily	Living	Scale;	
MMSE, Mini‐Mental State Examination; SD, standard deviation.
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costs.25 In addition, Obreli‐Neto et al26 found that adverse drug ef‐
fects	 related	 to	warfarin	 (eg,	 gastrointestinal	bleeding)	 are	a	 com‐
mon reason for hospital admissions. Ultimately, warfarin is highly 
noticed	in	The	American	Geriatrics	Society	Beers	Criteria® updated 
in 2019 in potentially clinically important drug‐drug interactions that 
should be avoided in older adults.27 Therefore, drugs that interact 
with warfarin in particular should be considered carefully when pre‐
scribed to older persons with and without diabetes.
Interactions	with	NSAIDs	were	common	in	our	study	population	
in	both	persons	with	and	without	diabetes	and	NSAIDs	 interacted	
most commonly with antihypertensive drugs. Concurrent use of 
NSAIDs	and	antihypertensive	drugs	may	diminish	the	antihyperten‐
sive effect.28	Moreover,	concurrent	use	of	NSAIDs	and	ACE	inhib‐
itors has been associated with nephrotoxicity especially in elderly 
patients and the combination should therefore be carefully consid‐
ered.29 Interactions with SSRIs and with SNRIs were more common 
among persons with diabetes probably due to a slightly higher prev‐
alence of depressive symptoms.
The strengths of this study include validated measurement tools 
(MMSE,	 AUDIT-C,	 IADL,	 GDS-15	 and	 EQ-5D)	 and	 a	 standardized	
health examination conducted by one physician only. In addition, the 
diagnosis of diabetes was made according to the ICD‐10 classifica‐
tion.	Furthermore,	the	SFINX-PHARAO® database contains updated 
and evidence‐based information of drugs used in Finland and the 
database is widely used as a support for clinical decision.
Our study has some limitations. First, this study was cross‐sec‐
tional, and therefore, the interactions or changes in the medication 
in future cannot be determined. In addition, our study was con‐
ducted in only one primary care district, and therefore, the results 
cannot be generalized directly on the national level. Furthermore, 
the consequences of drug‐drug interactions were not defined, that 
is the manifestations of the DDIs are uncertain. Finally, it should be 
noted that only a high risk for adverse effects was determined and a 
minor risk for adverse effects may exist.
4  | WHAT IS NE W AND CONCLUSION
In conclusion, clinically relevant drug‐drug interactions among older 
persons with and without diabetes are common and should be 
F I G U R E  1   Relative portions of drugs 
used	in	different	ATC	classes	among	
persons	with	and	without	diabetes.	ATC,	
Anatomical	Therapeutic	Chemical
Number of patients using the most commonly 
used drugs, n (%) Diabetes N = 182
No diabe‐
tes N = 176
A10	Drugs	used	in	diabetes 167	(91.8) 0	(0)
B01	Antithrombotic	agents 121	(66.5) 77	(43.8)
C09	Agents	acting	on	the	renin-angiotensin	system 120	(65.9) 77	(43.8)
C10	Lipid-modifying	agents 108	(59.3) 71	(40.3)
C07 Beta‐blocking agents 107	(58.8) 68	(38.6)
N02	Analgesics 101	(55.5) 87	(49.4)
A12	Mineral	supplements 62	(34.1) 54	(30.7)
C01 Cardiac therapy 55	(30.2) 38	(21.6)
A02	Drugs	for	acid	related	disorders 55	(30.2) 43	(24.4)
N05 Psycholeptics 50	(27.5) 31	(17.6)
TA B L E  2   Number of patients using 
the drugs most commonly used among 
persons with diabetes and corresponding 
numbers of patients without diabetes 
using these drugs
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monitored regularly. In particular, due to several comorbidities related 
to diabetes and commonly used drugs among persons with diabetes, 
interactions	with	NSAIDs,	warfarin	and	drugs	used	in	heart	diseases	
should be carefully considered to avoid drug adverse effects.
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TA B L E  3   Number of times different drugs were involved in clinically relevant drug‐drug interactions. Clinically relevant 
interaction	=	class	C	or	class	D	interaction	in	the	Sfinx® database
 
Number of times one drug was involved in a clini‐
cally relevant drug‐drug interaction among persons 
with diabetes
Number of times one drug was involved in a 
clinically relevant drug‐drug interaction among 
persons without diabetes
NSAIDsa 76 81
Warfarin 58 35
ACE	inhibitors	and	angiotensin	II	
receptor blockersb
33 30
Platelet aggregation inhibitorsc 29 26
Paracetamol 23 19
β‐blockersd 22 27
Diureticse 22 17
Statinsf 19 13
SSRIs and SNRIsg 18 7
ACE	inhibitor,	angiotensin-converting-enzyme	inhibitor;	NSAID,	non-steroidal	anti-inflammatory	drug;	SNRI,	serotonin	and	noradrenaline	reuptake	
inhibitor; SSRI, selective serotonin reuptake inhibitor.
aIbuprofen, naproxen, meloxicam, ketoprofen, diclofenac, etoricoxib. 
bLosartan,	ramipril,	valsartan,	candesartan,	enalapril,	eprosartan,	telmisartan,	perindopril.	
cAcetylsalicylic	acid,	clopidogrel,	dipyridamole.	
dBisoprolol, metoprolol, betaxolol, celiprolol, propranolol, atenolol, nebivolol. 
eHydrochlorothiazide, amiloride, spironolactone, furosemide, indapamide. 
fSimvastatin, fluvastatin, atorvastatin, rosuvastatin. 
gDuloxetine, citalopram, fluoxetine, escitalopram, venlafaxine. 
TA B L E  4   Frequency of having a high risk for drug adverse effect among persons with diabetes and without diabetes
Adverse effect Diabetes, n (%) (N = 182) No diabetes, n (%) (N = 176) P‐Value
Bleeding 46	(25.3) 37	(21.0) 0.341
Constipation 35	(19.2) 20	(11.4) 0.039
Anticholinergic	side	effects 30	(16.5) 17	(9.7) 0.056
Orthostatic hypotension 23	(12.6) 14	(8.0) 0.146
Sedation 11	(6.0) 7	(4.0) 0.371
QT prolongation 3	(1.6) 1	(0.6) 0.331
Seizures 1	(0.5) 0	(0)  
Serotonergic side effects 1	(0.5) 0	(0)  
Nephrotoxicity 0	(0) 1	(0.6)  
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